The stock of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) is a huge mover today! About 352,754 shares traded hands or 20.85% up from the average. CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has risen 467.55% since April 14, 2016 and is uptrending. It has outperformed by 462.86% the S&P500.
The move comes after 7 months positive chart setup for the $788.72 million company. It was reported on Nov, 16 by Barchart.com. We have $51.24 PT which if reached, will make NASDAQ:CLCD worth $220.84 million more.
CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Ratings Coverage
Out of 2 analysts covering CoLucid Pharmaceuticals (NASDAQ:CLCD), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. CoLucid Pharmaceuticals has been the topic of 4 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The rating was upgraded by Zacks to “Hold” on Thursday, September 3. As per Friday, August 14, the company rating was maintained by William Blair. The firm has “Buy” rating by Stifel Nicolaus given on Monday, September 19. The stock has “Buy” rating given by Stifel Nicolaus on Monday, October 24.
According to Zacks Investment Research, “CoLucid Pharmaceuticals, Inc. is a biopharmaceutical company which develops molecule for the treatment of migraine headaches. The company’s product candidate consists of oral Lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain, which are in different clinical trial. CoLucid Pharmaceuticals, Inc. is headquartered in Burlington, Massachusetts.”
More important recent CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on April 26, 2015, also Fool.com published article titled: “Why CoLucid Pharmaceuticals Inc. Soared As Much As 18% on Thursday”, Globenewswire.com published: “CoLucid Pharmaceuticals Announces Pricing of Public Offering of Common Stock” on September 09, 2016. More interesting news about CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) was released by: Prnewswire.com and their article: “CoLucid Pharmaceuticals, Inc., Raises $37.1 Million in Series C Preferred …” with publication date: January 13, 2015.
CLCD Company Profile
CoLucid Pharmaceuticals, Inc., incorporated on August 31, 2005, is a Phase III clinical-stage biopharmaceutical company. The Firm is engaged in developing a small molecule for the acute treatment of migraine headaches. The Company’s product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.